Brian Posner (Insider Trades), CFO of Alliqua BioMedical Inc. (ALQA), bought 2,500 shares of the company on Aug. 10. The average price per share was $5.02 for a total transaction of $12,550. Alliqua BioMedical Inc. provides advanced care solutions as well as custom manufacturing solutions to partners in the medical device and cosmetics industry. ALQA’s market cap is $130.68 million and P/S ratio is 15.66.
There have been 8 insider transactions with ALQA since April 2014. Posner conducted 4 of the 8 transactions, buying 10,000 shares of the company since May 2014. Posner’s earliest transaction decreased nearly 30% since the purchase, and the earliest insider buy in April 2014 also decreased about 30% since the purchase. The amount of insider buys increased from 3 in 2014, to 5 from January to August of this year. The volume of insider buys decreased from 719,286 share to 677,340 shares in the same period of time. 10% owner of ALQA, Celgene Corp. (Insider Trades), conducted a large volume of buys of 714,286 shares and 659,340 shares of ALQA in 2014 and 2015, respectively.
For more information about insider trades with Alliqua BioMedical Inc., click here.
Net income for the company decreased from the second quarter of 2014 to the second quarter of the following year. Alliqua BioMedical Inc. reported a net loss of $6.989 million, or $0.32 per share in the second quarter of 2015, compared to a net loss of $5.954 million, or $0.39 per share in the second quarter of 2014. Revenue during this same period increased 202%, from $1.037 million, to $3.136 million. Gross margin also increased from 19.3% in the second quarter of 2014 to 56.2% in the second quarter of 2015. David Johnson, CEO of Alliqua stated in addition to strong sales this quarter, the company also “successfully completed out acquisition of Celleration ahead of our original stated timeline and we raised important growth capital in a follow-on offering.” ALQA revenue increased 29.16%, and net income decreased 59.57% since 2010.
The company announced the closing of a merger with Celleration, Inc., a medical device company that develops the MIST Therapy therapeutic ultrasound platform for treatment of acute and chronic wounds. Johnson commented that the acquisition of Celleration would add, “nearly twenty sales resources.” The company announced a closing of the deal with Celleration Inc. for approximately $30.4 million of both cash and stock on June 1. According to GuruFocus.com data, Alliqua Inc. has a business predictability rank of 1 out of 5 stars. For more information about business predictability rank, click here.
For more stock trades of gurus in real time, visit GuruFocus’ Real Time Picks, a Premium Feature. Not a Premium Member of GuruFocus? Try it free for 7 days here.
